Business
Contineum Therapeutics to Present at September Investor Conferences
SAN DIEGO, August 28, 2025--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the following investor conferences in September.
About this update from Contineum Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1875,"height":663,"url":"https://media.zenfs.com/en/business-wire.com/e48701001c35970ac33e493a1d54595c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qipTaOBbawwsAR42OX5Zkw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMzOTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e48701001c35970ac33e493a1d54595c","width":960,"height":339},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/a0MjR_R4TbGlXTpiEa_dOA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04NDg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/e48701001c35970ac33e493a1d54595c","width":1200,"height":424}},"lazy":false},{"type":"text","content":"SAN DIEGO, August 28, 2025--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the following investor conferences in September.","length":390,"tagName":"p"},{"type":"text","content":"Cantor Global Healthcare Conference 2025 – fireside chat on Thursday, September 4, 2025, at 9:10 a.m. ET.","length":105,"tagName":"p"},{"type":"text","content":"Morgan Stanley 23rd Annual Global Healthcare Conference – fireside chat on Monday, September 8, 2025, at 8:30 a.m. ET.","length":118,"tagName":"p"},{"type":"text","content":"Baird 2025 Global Healthcare Conference – fireside chat on Tuesday, September 9, 2025, at 2:00 p.m. ET.","length":103,"tagName":"p"},{"type":"text","content":"An audio webcast of the presentations can be accessed on the Investors section of Contineum’s website. A replay of the webcasts will also be available.","length":151,"tagName":"p"},{"type":"text","content":"About Contineum Therapeutics","length":28,"tagName":"p"},{"type":"text","content":"Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary ...